[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB0722216D0 - Use of crth2 antagonist compounds - Google Patents

Use of crth2 antagonist compounds

Info

Publication number
GB0722216D0
GB0722216D0 GBGB0722216.9A GB0722216A GB0722216D0 GB 0722216 D0 GB0722216 D0 GB 0722216D0 GB 0722216 A GB0722216 A GB 0722216A GB 0722216 D0 GB0722216 D0 GB 0722216D0
Authority
GB
United Kingdom
Prior art keywords
antagonist compounds
crth2 antagonist
crth2
compounds
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0722216.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxagen Ltd
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Priority to GBGB0722216.9A priority Critical patent/GB0722216D0/en
Publication of GB0722216D0 publication Critical patent/GB0722216D0/en
Priority to PCT/GB2008/003843 priority patent/WO2009063215A2/en
Priority to US12/779,638 priority patent/US20110124683A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0722216.9A 2007-11-13 2007-11-13 Use of crth2 antagonist compounds Ceased GB0722216D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0722216.9A GB0722216D0 (en) 2007-11-13 2007-11-13 Use of crth2 antagonist compounds
PCT/GB2008/003843 WO2009063215A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds
US12/779,638 US20110124683A1 (en) 2007-11-13 2010-05-13 Use of CRTH2 Antagonist Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0722216.9A GB0722216D0 (en) 2007-11-13 2007-11-13 Use of crth2 antagonist compounds

Publications (1)

Publication Number Publication Date
GB0722216D0 true GB0722216D0 (en) 2007-12-27

Family

ID=38896181

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0722216.9A Ceased GB0722216D0 (en) 2007-11-13 2007-11-13 Use of crth2 antagonist compounds

Country Status (2)

Country Link
GB (1) GB0722216D0 (en)
WO (1) WO2009063215A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
JP5491416B2 (en) 2008-02-01 2014-05-14 パンミラ ファーマシューティカルズ，エルエルシー． N, N-2-substituted aminoalkylbiphenyl antagonist of prostaglandin D2 receptor
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Cyclic diaryl ether as antagonists of prostaglandin d2 receptors
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
CA2729292C (en) 2008-07-03 2013-09-03 Amira Pharmaceuticals, Inc. Phenoxyphenyl sulfide, sulfinyl and sulfonyl antagonists of prostaglandin d2 receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
WO2010142934A1 (en) * 2009-06-12 2010-12-16 Pulmagen Therapeutics (Asthma) Limited Indole derivatives as ligands of crth2 receptors
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2011017201A2 (en) 2009-08-05 2011-02-10 Amira Pharmaceuticals, Inc. Dp2 antagonist and uses thereof
CA2782085A1 (en) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
PT2558447E (en) 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
HUE028972T2 (en) 2011-04-14 2017-01-30 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
WO2013088109A1 (en) * 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
MA39750B1 (en) 2014-03-17 2018-12-31 Idorsia Pharmaceuticals Ltd Derivatives of aza-indol-acetic acid and their use as modulators of prostaglandin receptors d2
MX2016011900A (en) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators.
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
UA123156C2 (en) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд Crystalline forms
WO2017104728A1 (en) * 2015-12-16 2017-06-22 国立大学法人東京大学 Medicine for treating food allergy
WO2018014869A1 (en) * 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 Indole derivative used as crth2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
SI2046740T1 (en) * 2006-07-22 2012-12-31 Oxagen Limited Compounds having crth2 antagonist activity

Also Published As

Publication number Publication date
WO2009063215A2 (en) 2009-05-22
WO2009063215A3 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
GB0722216D0 (en) Use of crth2 antagonist compounds
GB0722203D0 (en) Use of CRTH2 antagonist compounds
HUS1900009I1 (en) Novel compounds and compositions and methods of use
IL206959A0 (en) Compounds having crth2 antagonist activity
HK1130256A1 (en) Compounds having crth2 antagonist activity
HK1147674A1 (en) Heterocyclic compounds as crth2 receptor antagonists crth2
IL202679A0 (en) Particulates of a crth2 antagonist
AP2008004406A0 (en) Methods of managing timberland
PL2328545T3 (en) Use of glucosylglycerol
HK1160925A1 (en) Use of athepsin
AP2784A (en) Methods of managing timberland
EP2118174A4 (en) Use of tocopherol
ZA200806508B (en) Salt of CD80 Antagonist
ZA200900393B (en) Compounds having CRTH2 antagonist activity
GB0801674D0 (en) Compounds having CRTH2 antagonist activity
PL2237782T3 (en) Use of tetrahydropyrimidines
GB201114396D0 (en) Location of basesation
GB0800874D0 (en) Compounds having CRTH2 antagonist activity
GB0801131D0 (en) Compounds having CRTH2 antagonist activity
GB0801132D0 (en) Compounds having CRTH2 antagonist activity
GB0801672D0 (en) Compounds having crth2 antagonist activity
GB0801671D0 (en) Compounds having crth2 antagonist activity
GB0820526D0 (en) Compounds having crth2 antagonist activity
GB0624176D0 (en) Compounds having CRTH2 antagonist activity
PL383758A1 (en) New application of undecane-2-on

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)